Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 5/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4433094 | 0.85 | FGFR1 (0.39) | EPHB4FGFR1KDRCRHR1CCR1 | |
| SCHEMBL27773138 | 0.83 | CRHR1 (0.41) | EPHB4FGFR1KDRCRHR1CCR1 | |
| SCHEMBL3929419 | 0.82 | FGFR1 (0.36) | EPHB4FGFR1KDRCRHR1CCR1 | |
| SCHEMBL4432574 | 0.82 | ALDH1A1 (0.43) | EPHB4FGFR1KDRCRHR1DYRK1A | |
| SCHEMBL4295173 | 0.79 | KDR (0.48) | KDR | |
| SCHEMBL4552874 | 0.78 | HSD17B1 (0.43) | EPHB4FGFR1KDRDYRK1ARAB9A | |
| SCHEMBL4431915 | 0.77 | EPHB4 (0.52) | EPHB4FGFR1KDR | |
| SCHEMBL4442524 | 0.76 | AURKA (0.40) | EPHB4FGFR1KDR | |
| SCHEMBL4442527 | 0.75 | EPHB4 (0.39) | EPHB4FGFR1KDR | |
| SCHEMBL3634203 | 0.73 | EPHB4 (0.38) | EPHB4FGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101668749-A | Novel pyrimidine derivatives 698 | ASTRAZENECA AB | 2010-03-10 | — | — | CN | disclosed |
| EP-2150545-A1 | N' - (PHENYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINE DERIVATIVES AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS | AstraZeneca AB (SE) | 2010-02-10 | — | — | EP | disclosed |
| EP-2132184-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | AstraZeneca AB (SE) | 2009-12-16 | — | — | EP | disclosed |
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| WO-2008132505-A1 | N' - (PHENYL) -N- (MORPHOLIN-4-YL-PYRIDIN-2-YL) -PYRIMIDINE-2, 4-DIAMINE DERIVATIVES AS EPHB4 KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE CONDITIONS | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | US | disclosed |
| WO-2008104754-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | ASTRAZENECA AB (SE) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242663-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | EPHB4, EPHB1, NME2 | EPHB4 1/4885FGFR1 661/4885KDR 1003/4885 |
| US-20090036440-A1 | NOVEL PYRIMIDINE DERIVATIVES - 816 | EPHB4, EPHB6, EPHB1 | EPHB4 1/4885FGFR1 700/4885KDR 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.